Los puntos clave no están disponibles para este artículo en este momento.
GSK is partnering with venture firm Flagship Pioneering in a multipronged effort to develop up to 10 new medicines and vaccines. The two firms are providing 150 million collectively up front. GSK agreed to pay Flagship and any portfolio companies that enter the arrangement up to 720 million in additional development and milestone payments. The collaboration stems from Flagship's Pioneering Medicines initiative, which has spearheaded partnerships with Novo Nordisk, Pfizer, and the Cystic Fibrosis Foundation.
Rowan Walrath (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: